Status:
RECRUITING
Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction
Lead Sponsor:
Centre Hospitalier de Corbie
Conditions:
HFrEF - Heart Failure With Reduced Ejection Fraction
Cardiac Rehabilitation
Eligibility:
All Genders
40-75 years
Brief Summary
Exercise intolerance, measured as peak oxygen consumption (VO₂peak) during exercise in patients with heart failure with reduced ejection fraction (HFrEF). Change in VO₂peak (ΔVO₂peak), which serves as...
Detailed Description
Key Takeaways VO₂peak is a clinically relevant, prognostic measure in HFrEF. .ExCR benefits are heterogeneous, partly due to variable cardiac and muscular adaptations. c-miRNAs may mediate or indicate...
Eligibility Criteria
Inclusion
- Heart failure with reduced ejection fraction \< 40%
- NYHA functional class ≥ II
- Clinically stable for at least 6 weeks
- On optimized medical therapy for at least 6 weeks
- Prescription for phase II cardiac rehabilitation
- BMI between 20-30 kg·m-²
- Physical activity level: sedentary or physically active but untrained
- Signed informed consent to participate in the study
- Affiliation to the French national health insurance system
Exclusion
- Contraindication to regular adapted physical activity
- Uncontrolled arterial hypertension
- Secondary respiratory disease such as emphysema or chronic obstructive pulmonary disease (COPD)
- Secondary cardiovascular disease
- Individuals under legal protection or deprived of liberty
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
November 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2027
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT07164911
Start Date
November 25 2025
End Date
November 30 2027
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital center of Corbie
Corbie, France, 80800